Login / Signup

Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial.

Hirotaka WatadaAkane TakamiRobert SprangerAtsushi AmanoYasuhiro HashimotoElisabeth Niemoeller
Published in: Diabetes care (2020)
This phase 3 study demonstrated superior glycemic control and fewer gastrointestinal adverse events with iGlarLixi than with Lixi, which may support it as a new treatment option for Japanese patients with T2DM that is inadequately controlled with OADs.
Keyphrases
  • glycemic control
  • type diabetes
  • blood glucose
  • weight loss
  • insulin resistance
  • double blind
  • open label
  • clinical trial
  • randomized controlled trial
  • skeletal muscle
  • study protocol
  • placebo controlled